The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
Abstract
BACKGROUND: Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited statistical power, uncertain nodal radiotherapy target volumes, and a scarcity of data on relevant clinical subgroups. METHODS: We conducted a noninferiority trial in which patients with clinically node-negative primary T1 to T3 breast cancer (tumor size, T1, ≤20 mm; T2, 21 to 50 mm; and T3, >50 mm in the largest dimension) with one or two sentinel-node macrometastases (metastasis size, >2 mm in the largest dimension) were randomly assigned in a 1:1 ratio to completion axillary-lymph-node dissection or its omission (sentinel-node biopsy only). Adjuvant treatment and radiation therapy were used in accordance with national guidelines. The primary end point was overall survival. We report here the per-protocol and modified intention-to-treat analyses of the prespecified secondary end point of recurrence-free survival. To show noninferiority of sentinel-node biopsy only, the upper boundary of the confidence interval for the hazard ratio for recurrence or death had to be below 1.44. RESULTS: Between January 2015 and December 2021, a total of 2766 patients were enrolled across five countries. The per-protocol population included 2540 patients, of whom 1335 were assigned to undergo sentinel-node biopsy only and 1205 to undergo completion axillary-lymph-node dissection (dissection group). Radiation therapy including nodal target volumes was administered to 1192 of 1326 patients (89.9%) in the sentinel-node biopsy-only group and to 1058 of 1197 (88.4%) in the dissection group. The median follow-up was 46.8 months (range, 1.5 to 94.5). Overall, 191 patients had recurrence or died. The estimated 5-year recurrence-free survival was 89.7% (95% confidence interval [CI], 87.5 to 91.9) in the sentinel-node biopsy-only group and 88.7% (95% CI, 86.3 to 91.1) in the dissection group, with a country-adjusted hazard ratio for recurrence or death of 0.89 (95% CI, 0.66 to 1.19), which was significantly (P<0.001) below the prespecified noninferiority margin. CONCLUSIONS: The omission of completion axillary-lymph-node dissection was noninferior to the more extensive surgery in patients with clinically node-negative breast cancer who had sentinel-node macrometastases, most of whom received nodal radiation therapy. (Funded by the Swedish Research Council and others; SENOMAC ClinicalTrials.gov number, NCT02240472.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912
Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J. H., Mansel, R. E., Cataliotti, L., Westenberg, A. H., Klinkenbijl, J. H. G., Orzalesi, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70460-7 · Cited by 1,871
Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Hunt, K. K., Morrow, M., & Ballman, K. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f08f32 · Cited by 1,263
Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70035-4 · Cited by 1,233
Self-citationPer-Protocol Analyses of Pragmatic Trials
Hernán, M. A., & Robins, J. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmsm1605385 · Cited by 660
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
Jagsi, R., Chadha, M., Moni, J., Ballman, K. V., Laurie, F., Buchholz, T. A., Giuliano, A. E., & Haffty, B. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5838 · Cited by 393
Bartels, S. A. L., Donker, M., Poncet, C., Sauvé, N., Straver, M. E., van de Velde, C. J. H., Mansel, R. E., Blanken, C., Orzalesi, L., Klinkenbijl, J. H. G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01565 · Cited by 380
Tolaney, S. M., Garrett-Mayer, E., White, J., Blinder, V. S., Foster, J. C., Amiri-Kordestani, L., Hwang, E. S., Bliss, J. M., Rakovitch, E., Perlmutter, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03613 · Cited by 229
on behalf of the SENOMAC Trialists’ Group, de Boniface, J., Frisell, J., Andersson, Y., Bergkvist, L., Ahlgren, J., Rydén, L., Olofsson Bagge, R., Sund, M., Johansson, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3361-y · Cited by 174
Self-citation
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Metadata
- Authors
- de Boniface, J., Filtenborg Tvedskov, T., Rydén, L., Szulkin, R., Reimer, T., Kühn, T., Kontos, M., Gentilini, O. D., Olofsson Bagge, R., Sund, M., Lundstedt, D., Appelgren, M., Ahlgren, J., Norenstedt, S., Celebioglu, F., Sackey, H., Scheel Andersen, I., Hoyer, U., Nyman, P. F., Vikhe Patil, E., Wieslander, E., Dahl Nissen, H., Alkner, S., Andersson, Y., Offersen, B. V., Bergkvist, L., Frisell, J., & Christiansen, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1163-1175
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852420
- Cited by
- 307
- References
- 13
- FWCI
- 46.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. https://app.cochat.ai/papers/10.1056/nejmoa2313487
- The paper
- de Boniface, J., Filtenborg Tvedskov, T., Rydén, L., Szulkin, R., Reimer, T., Kühn, T., Kontos, M., Gentilini, O. D., Olofsson Bagge, R., Sund, M., Lundstedt, D., Appelgren, M., Ahlgren, J., Norenstedt, S., Celebioglu, F., Sackey, H., Scheel Andersen, I., Hoyer, U., Nyman, P. F., . . . Christiansen, P. (2024). Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2313487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.